التفاصيل البيبلوغرافية
| العنوان: |
Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome. |
| المؤلفون: |
Giordano, Salvatore, Ielapi, Jessica, Salerno, Nadia, Cersosimo, Angelica, Lucchino, Alessandro, Laschera, Alessandro, Canino, Giovanni, Di Costanzo, Assunta, De Rosa, Salvatore, Torella, Daniele, Sorrentino, Sabato |
| المصدر: |
Reviews in Cardiovascular Medicine; Oct2024, Vol. 25 Issue 10, p1-12, 12p |
| مستخلص: |
Acute coronary syndromes (ACSs) represent a significant global health challenge arising from atherosclerotic cardiovascular disease (ASCVD), with elevated low-density lipoprotein cholesterol (LDL-C) levels being a primary contributor. Despite standard statin therapy, individuals with ACS remain at high risk for recurrent cardiovascular events, particularly in the initial post-ACS period. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), such as evolocumab and alirocumab, offer a potential strategy to reduce LDL-C levels further and mitigate this residual risk. This review delves into the molecular mechanisms, effects on cholesterol metabolism, inflammatory modulation, and clinical outcomes associated with early administration of PCSK9 inhibitors following ACS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Reviews in Cardiovascular Medicine is the property of IMR Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder